SGO 2022 Annual Meeting - Ovarian Cancer Research

Below find some interesting ovarian cancer research studies I heard at the SGO meeting.

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

Long Term Survival of GOG 252 'Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study' J. Walker

#SGOmtg. Dr Walker GOG 252 - no gross residual disease population - Can you completely resect? Can you get CA125 to less than 10 in 3 cycles. #gyncsm pic.twitter.com/qMksxlPgFx

— Dee Sparacio (@womenofteal) March 18, 2022

 

 What's Next After Bevaciumab Resistance? Targeting Metabolic Vulnerabilities in Ovarian Cancer –  D. Glassman GLSi is a novel therapeutic strategy to treat AVA-resistant ovarian cancer

#SGOmtG Dr Glassman : Bevaczumab resistance in OC
GLS expression GLS inhibitor and hypoxia , #gycsm pic.twitter.com/A7kjIBHIqB

— Dee Sparacio (@womenofteal) March 18, 2022

 

Final Overall Survival Results from SOLO3: Phase III Trial Assessing Olaparib Monotherapy Versus Non-Platinum Chemotherapy in Heavily Pretreated Patients with Germline BRCA1 and/or BRCA2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer –  R. Penson

Investigation of PARP Inhibitor Resistance Through the Analysis of Serially Collected Circulating Tumor DNA (ctDNA) in Ovarian Cancer Patients – Speaker: Y. Kim 

#SGOMtg Dr Kim PARP progression and gene mutations #gyncsm pic.twitter.com/8BHkdtz1LK

— Dee Sparacio (@womenofteal) March 18, 2022

 

Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) – Speaker: K. Moore

Dr Moore global study of use of maintenance therapy #SGOMtg #gyncsm pic.twitter.com/GQXBwelTEz

— Dee Sparacio (@womenofteal) March 18, 2022

 

Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and Psychometric Testing Results of a Patient-Centered Knowledge Measure – Speaker: L. Meyer

Yes!! Dr. Larissa Meyer: Knowledge is a prerequisite to informed choice. Development of KnoMOR (Knowledge Measurement for Ovarian Cancer Research) Shared decision making tool. #SGOmtg #GYNcsm pic.twitter.com/miuAi5ZGuD

— Annie Ellis (@Stigetta) March 18, 2022

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis – Speaker: M. Hardesty

 

Hardest OVARIO trial #SGOmtg heavily pretreated population.
53% had PFS at 28 months. S not available at this time. #gyncsm pic.twitter.com/wr9Ze4NMOP

— Dee Sparacio (@womenofteal) March 19, 2022

 

Prospective, Randomized Trial of Streamlined Genetic Education and Testing for Patients with High Grade Epithelial Ovarian, Fallopian and Peritoneal Cancer – Speaker: R. Previs

Dr. Rebecca Previs presents results of video assisted streamlined genetic education and testing for ovarian cancer #SGOmtg #GYNcsm #PECPatAdv pic.twitter.com/EkzCqvk3qo

— Annie Ellis (@Stigetta) March 19, 2022

 Effectiveness of Platinum-Based Chemotherapy after Progression on Poly ADP Ribose Polymerase (PARP) Inhibitor in Epithelial Ovarian Cancer – Speaker: K. Dugan

#SGOmtg Dr Dugan For patients who progress after PARP retreatment with platinum drugs is reasonable #gyncsm pic.twitter.com/AYBB2bjES7

— Dee Sparacio (@womenofteal) March 19, 2022

Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox

A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial – Speaker: J. Liu , This is a Niraparib and Anlotinib ( kinase inhibitor) combo used in Platinum-Resistant OC (ANNIE Study) Promising combo With tolerable toxicity . PPMD1 mutation may be what leads to resistance in niraparib.

 Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer – D. Richardson

#SGOmtg Ph1 Expansion Study of Upifitamab Rilsodotin (UpRi NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian
Cancer - Dr Richardson , 97 patients in 2 groups , no severe toxicity, prior lines
ORR 44% in NaPi 2b expression patients #gyncsm pic.twitter.com/c8a3Idtj0A

— Dee Sparacio (@womenofteal) March 19, 2022

Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer

#SGOmtg Ovarian Cancer Treated with the Novel Engineered
Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab ARTISTRY-1 – Dr I. Winer
16 patients treated, 5 had response. Well tolerated. Evidence of tumor response , FDA fast track Designation #gyncsm pic.twitter.com/9tyvTZFOvK

— Dee Sparacio (@womenofteal) March 19, 2022

 

Late Breaking Abstracts:

#SGOmtg Dr Matulonis Soraya study : High folate expressing ovarian cancer treated with mirvetuximab MIRV antibody drug conjugate ORR 34%, mDOR 6.9 months 5 complete responses mPFS 5.4 mo
AE ocular events( blurred vision) were reversible , nausea #gyncsm pic.twitter.com/oNV8XjpoEG

— Dee Sparacio (@womenofteal) March 19, 2022

#SGOmtg PRIME study - niraparib as maintenance in newly dx adv OC individual dosing
PFS 24.8 months with Niraparib vs 8.3 months in placebo
Immature OS . #gyncsm pic.twitter.com/kbAz1QBJzk

— Dee Sparacio (@womenofteal) March 20, 2022

#SGOmtg Dr Gershenson presenting on LGSOC using NGS
Characteristics : Young age, relative chem resistance, responds to endocrine therapy #gyncsm pic.twitter.com/QzYZfJ7SGw

— Dee Sparacio (@womenofteal) March 20, 2022

Dr David Gershenson presenting study showing better survival in women with low grade serous ovarian cancer whose tumors have MAPK mutations ⁦@RareOvarCancers⁩ #sgomtg pic.twitter.com/7c2ydfwwzN

— Karen Lu (@karenluMD) March 20, 2022

 

Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets

RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer –  S. Adams

#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02

— Dee Sparacio (@womenofteal) March 20, 2022

#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02

— Dee Sparacio (@womenofteal) March 20, 2022

Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into the Tumor Microenvironment in Responding Patients with Recurrent Ovarian Cancer – N. Gaulin

The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana

#SGOMtg Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana#gyncsm pic.twitter.com/pHODjYeAPv

— Dee Sparacio (@womenofteal) March 20, 2022

Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment of High Grade Serous Ovarian Carcinoma –  L. Brubaker

#SGOMtg Dr Brubaker CBX2 ( epigenetic transcription regulator has high expression in HGSOC , poor survival.
Mouse study - less tumor when CBX2 knocked down .
CBX2 directly regulates micrenvironment
Working on CBX2 inhibitor . #gyncsm pic.twitter.com/vOkLKxauYx

— Dee Sparacio (@womenofteal) March 20, 2022

 Stay tuned for a post on Cervical Cancer.

Dee

Every Day is a Blessing! 

SGO 2022 Annual Meeting - Disparities and Equity Research Across Gyn Cancers

The #BreakingBarriers and #BuildingBridges theme of this year's meeting was evident in the presentations on equity and disparities.

Breaking Barriers : Toward Greater Equity in Gyn Oncology Care : Scientific Plenary I

 

Black and Hispanic Patient Representation in NCCN-Recommended Systemic Therapy Regimens for Endometrial Cancer – A. Kulkarni

Race and ethnicity are under-reported in trials supporting @NCCN guideline-listed systemic treatment regimens. There is a clear unmet need to improve #clinicaltrial enrollment among underrepresented minorities in #EndometrialCancer #gyncsm #SGOMtg #SGO2022 pic.twitter.com/u3QzCE4mG5

— Shannon Westin (@ShannonWestin) March 18, 2022

 

 

Effect of Racism on Cancer Care in Women with Gynecologic Cancers – Speaker: D. Lewis

#SGOmtg Dr Lewis presents a study of race based stress and treatment interruptions - interventions are needed #gyncsm pic.twitter.com/TTJLgozD2m

— Dee Sparacio (@womenofteal) March 18, 2022

 

Neighborhood Economic Vulnerability is a Predictor for Patterns of Care and Outcomes for People with Uterine Cancer – Neighborhood economic vulnerability is a predictor for patterns of care and outcomes for people with uterine cancer

#SGOmtg Dr Gamble NY study, geo coded patient address and area of deprivation index and guideline adherence for uterine cancer patients. #gyncsm intersection of race and affluence pic.twitter.com/Vd9bOwBlxO

— Dee Sparacio (@womenofteal) March 18, 2022

 

Overspending Driven by Dose-Specific Packaging of Lenvatinib for Endometrial Cancer – E. Aviki Financial toxicity of drug packaging for endometrial cancer. 

#SGOmtg @EmelineAvikiMD Overspending on Lenvatinib for endometrial cancer. Dose packaging ( blister Pack) impacts cost of treatment when dose reductions occur
New Dose exchange program by Essai- That is Progress! pic.twitter.com/Se62p463Al

— Dee Sparacio (@womenofteal) March 18, 2022

ON THE GROUND COMMITMENT from @EisaiUS to create/promote an UNRESTRICTED pill exchange program. LIVE @SGO_org #SGOmtg
➡️This is how change is made
➡️This is why research is meaningful
➡️This is how our work translates into REAL benefit for pts
🎩Hats off to Dr @EmelineAvikiMD

— Fumiko Ladd Chino, MD (@fumikochino) March 18, 2022

Distillation -  Dr Doll “Health equity research requires scientific rigor”

If we can make structural change in drug packaging, we can make structural change elsewhere. An awesome distillation by @KemiDoll this afternoon. Thanks to the presenters for this great session. #SGO2022 #sgomtg pic.twitter.com/pvp4iujJjY

— Allison Barrie (@AllisonBarrieMD) March 18, 2022

#SGOmtg Dr Doll reviews health equity research
Equity is always multi-dimensional #gyncsm pic.twitter.com/ieALZBuKc5

— Dee Sparacio (@womenofteal) March 18, 2022

 

 

Do U.S. Screening Guidelines Contribute to Higher Stage and Worse Survival in our Youngest and Oldest Cervical Cancer Patients? C. Sitler

#SGOmtg Dr Sitler age related Cervical Cancer mortality and guideline screening
Elder dx at later stage , #gyncsm pic.twitter.com/4xxMWj8mJy

— Dee Sparacio (@womenofteal) March 18, 2022

 

 

Impact of Medicaid Expansion on Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis – Speaker: S. Huepenbecker

#SGOmtg Huepenbecker Medicaid expansion impact on postoperative mortality in gyn cancers difference in difference analysis NCDB data #gyncsm pic.twitter.com/xOKOFEuuYN

— Dee Sparacio (@womenofteal) March 18, 2022

 

 

Health Equity is the Bullseye of the Quadruple Aim: A Social and Moral Imperative – ABOG Speaker: J. Nwando Olayiwola, MD, MPH, FAAFP

.@DrNwando delivering an incredible keynote to kick off #SGO2022. "Until the system assigns equal value to the experiences and pain of non-Whites, we cannot move forward." 🔥

⭐️ Big takeaway? Globally improving quality of care ≠ improving disparities.#SGOmtg @SGO_org pic.twitter.com/nKlgxxtIPj

— Sarah J. Mah, MD (@SarahJMahMD) March 18, 2022

#SGOmtg. @DrNwando Making an Impact For Health Equity #gyncsm
We need to fix what is broken in society . Assign equal value to experience and Pain of non-whites . Bring patients in for input on materials . Give power back to the communities we serve. pic.twitter.com/m27JD6Jo04

— Dee Sparacio (@womenofteal) March 18, 2022

Moving Upstream. #buildingbridges #SGOMtg @DrNwando pic.twitter.com/PLKedmOScr

— Erin Stevens (@erinstevensmd) March 18, 2022

 

Focused Plenary Session III: Inequities during the Pandemic and Beyond 

 
Refusal of Gynecologic Cancer Surgery is a Surgical and Oncologic Disparity, Not an Issue of Noncompliance – Speaker: D. Samuel

#SGOmtg Samuel : there are several factors associated w./ refusal of surgery despite access, Retro study ,778,000 patients
Over 70 yrs, black Adv stage , treatment at community center factors in refusal #gyncsm pic.twitter.com/5cCmjxx3Dg

— Dee Sparacio (@womenofteal) March 19, 2022

 

 Socio-Ecological Model of Barriers to Cascade Testing for Hereditary Cancer Syndromes: Systematic Review of the Literature – Speaker: X. Li

#SGOmtg Dr Li hereditary cancers and cascade genetic testing can reduce mortality but there are barriers .— Individual, interpersonal and community and Society/ policy. #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

 

 Geospatial Approaches for Surveillance of Disparities in Clinical Trial Enrollment – Speaker: J. Gordon

#SGOmtg Dr Gordon
Geospatial information is useful to understand social vulnerability of women with endometrial cancer as well as improve care and clinical trial participation. #gyncsm pic.twitter.com/gzK7i6RKYe

— Dee Sparacio (@womenofteal) March 19, 2022

 

 

When Being Insured is Not Enough: The Effect of Insurance Type on Survival in Cervical Cancer – Speaker: C. Kucera

Calen Kucera bringing light to insurance disparities and representing @WalterReedGME at the @SGO_org annual meeting.#SGOMtg pic.twitter.com/M8LhORyV5S

— Collin Sitler (@CollinSitler) March 19, 2022

 

 

Race Matters: Disparities in the Use of Maintenance Therapy in Ovarian Cancer (OC) – Speaker: E. Schrader

#SGOmtg Dr Schrader maintenance therapy in OC did not vary by insurance status. Black women were less likely to be treated maintenance therapy. #gyncsm pic.twitter.com/XYi1c0MzNE

— Dee Sparacio (@womenofteal) March 19, 2022

Thank you Drs Westin, Chino, Ma, Stevens, and Sitler for tweeting their the insights.

 

 Dee

Every Day is a Blessing!